Abstract
Behavior of topotecan, DNA topoisomerase I inhibitor, was studied in aqueous solutions by optical methods. Topotecan absorption spectra were recorded in the pH range 0.5–11.5 and its pKa were determined. Quantum chemical calculations were made for all charge states of the topotecan molecule in lactone and carboxylate form. The calculated absorption maxima agree well with the experimental data. Protonation of the topotecan D ring (pKa ≈ 3.6) was revealed. Comparison of experimental and calculated data showed topotecan structure with a proton at the oxygen atom at C16a rather than N4 to be the most preferable. Topotecan molecules were shown to form dimers at concentrations above 10–5M. Topotecan dimerization is accompanied by an increase in the pKa of hydroxy group of the A ring from 6.5 ([TPT] = 10–6M) to 7.1 ([TPT] = 10–4M), which indicates participation of this group in dimer stabilization, perhaps due to intermolecular hydrogen bonding with N1 of the B ring of a neighboring molecule. Probable dimer structures were proposed. The topotecan dimerization constant was determined, K = (4.0 ± 0.7) · 103M–1.
Similar content being viewed by others
References
Gupta, M., Fuijimori, A., and Pommier, Y., Biochim. Biophys. Acta, 1995, vol. 1261, pp. 1–14.
Wang, J.C., Annu. Rev. Biochem., 1996, vol. 65, pp. 635–692.
Kingsbury, W.D., Boehm, J.C., Jakas, D.R., Holden, K.G., Hecht, S.M., Gallagher, G., Caranfa, M.J., McCabe, F.L., Faucett, L.F., Johnson, R.K., and Hertzberg, R.P., J. Med. Chem., 1991, vol. 34, pp. 98–107.
Chen, A.Y. and Liu, L.F., Annu. Rev. Pharmacol. Toxicol., 1994, vol. 94, pp. 194–218.
Hsiang, Y.H., Hertzberg, R., Hecht, S., and Liu, L.F., J. Biol. Chem., 1985, vol. 260, pp. 14873–14878.
Hertzberg, R.P., Busby, R.W., Caranfa, M.J., Holden, K.G., Johnson, R.K., Hecht, S.M., and Kingsbury, W.D., J. Biol. Chem., 1990, vol. 265, pp. 19287–19295.
Rothenberg, M.L., Ann. Oncol., 1997, vol. 8, pp. 837–855.
Li, L.H., Frase, T.J., Olin, E.J., and Bhuyan, B.K., Cancer Res., 1972, vol. 32, pp. 2643–2650.
Kuwahara, J., Suzuki, T., Funakoshi, K., and Sugiura, Y., Biochemistry, 1986, vol. 25, pp. 1216–1221.
Hertzberg, R.P., Caranfa, M.J., and Hecht, S.M., Biochemistry, 1989, vol. 28, pp. 4629–4638.
Yang, A., Strode, J.T., Spielmann, H.P., Wang, A.H.-G., and Burke, T.G., J. Am. Chem. Soc., 1998, vol. 120, pp. 2979–2980.
Yao, S., Murali, D., Seetharamulu, P., Haridas, K., Petluru, P.N.V., Reddy, D.G., and Hausheer, F.H., Cancer Res., 1998, vol. 58, pp. 3782–3786.
Gottlieb, J.A., Guarino, A.M., Call, J.B., Oliverio, V.T., and Bloc, J.B., Cancer. Chemother. Rep., 1970, vol. 54, pp. 461–470.
Nabiev, I., Fleury, F., Kudelina, I., Pommier, Y., Charton, F., Riou, J-F., Alix, A.J.P., and Manfait, M., Biochem. Pharmacol., 1998, vol. 55, pp. 1163–1174.
Dewar, M.J.S., Zoebisch, E.G., Healy, E.F., and Stewart, J.P., J. Am. Chem. Soc., 1985, vol. 107, pp. 3902–3909.
Zerner, M.C., Loew, G.H., Kirchner, R.F., and Mueller-Westerhoff, U.T., J. Am. Chem. Soc., 1980, vol. 102, pp. 589–599.
Lackey, K., Sternbach, D.D., Croom, D.K., Emerson, D.L., Evans, M.G., Leitner, P.L., Luzzio, M.J., McIntyre, G., Vuong, A., Yates, J., and Besterman, J.M., J. Med. Chem., 1996, vol. 39, pp. 713–719.
Fassberg, J. and Stella, V.J.J., Pharm. Sci., 1992, vol. 81, pp. 676–684.
McPhail, A.T. and Sim, G.A., J. Chem. Soc. (B), 1968, pp. 923–928.
Oleinikov, V.A., Mochalov, K.E., Sukhanova, A.V., Ermishev, M.A., Kudelina, I.A., Ustinova, O.A., Streltsov, S.A., Grokhovsky, S.L., Zhuze, A.L., Jardiller, J.-C., and Nabiev, I.R., FEBS Lett. (in press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Strel'tsov, S.A., Grokhovskii, S.L., Kudelina, I.A. et al. Interaction of Topotecan, DNA Topoisomerase I Inhibitor, with Double-Stranded Polydeoxyribonucleotides. 1. Topotecan Dimerization in Solution. Molecular Biology 35, 365–373 (2001). https://doi.org/10.1023/A:1010422711817
Issue Date:
DOI: https://doi.org/10.1023/A:1010422711817